The stock of Chimerix Inc (NASDAQ:CMRX) hit a new 52-week high and has $7.07 target or 7.00% above today’s $6.61 share price. The 7 months bullish chart indicates low risk for the $307.50M company. The 1-year high was reported on Mar, 23 by Barchart.com. If the $7.07 price target is reached, the company will be worth $21.53 million more. About 301,200 shares traded. Chimerix Inc (NASDAQ:CMRX) has risen 37.92% since August 16, 2016 and is uptrending. It has outperformed by 30.10% the S&P500.
Cadiz Inc. is a land and water resource development firm with approximately 45,000 acres of land in three areas of eastern San Bernardino County, California. The company has market cap of $316.01 million. The Company’s primary business is to acquire and develop land with water resources for various uses, including groundwater supply, groundwater storage and agriculture. It currently has negative earnings. It is focused on the development of the Cadiz Valley Water Conservation, Recovery and Storage Project, which captures and conserves millions of acre-feet of native groundwater being lost to evaporation from the aquifer system beneath its approximately 34,000-acre property in the Cadiz and Fenner valleys of eastern San Bernardino County and deliver it to water providers throughout Southern California.
It is down 81.65% since August 16, 2016 and is uptrending. It has outperformed by 73.83% the S&P500.
Water Asset Management Llc holds 24.95% of its portfolio in Cadiz Inc for 2.96 million shares. American Assets Capital Advisers owns 889,797 shares or 7.31% of their US portfolio. Moreover, Elkhorn Partners Limited Partnership has 4.39% invested in the company for 579,000 shares. The United Kingdom-based Odey Asset Management Group Ltd has invested 1.7% in the stock. Kings Point Capital Management, a New York-based fund reported 75,000 shares.
Since January 1, 0001, it had 7 insider buys, and 1 sale for $4.45 million activity.
Investors sentiment decreased to 0.94 in Q4 2016. Its down 0.11, from 1.05 in 2016Q3. It fall, as 16 investors sold Chimerix Inc shares while 31 reduced holdings. 12 funds opened positions while 32 raised stakes. 30.20 million shares or 8.41% less from 32.97 million shares in 2016Q3 were reported. Gsa Prns Llp reported 261,167 shares. 29,098 were reported by State Board Of Administration Of Florida Retirement. Leisure Management, a California-based fund reported 30,460 shares. Public Employees Retirement Association Of Colorado has 0% invested in Chimerix Inc (NASDAQ:CMRX) for 13,842 shares. Susquehanna Group Limited Liability Partnership reported 0% stake. Parametric Associate Lc reported 254,945 shares. Commonwealth Of Pennsylvania Public School Empls Retrmt holds 23,077 shares. Geode Capital Management Limited Liability Corp owns 305,486 shares. New York State Common Retirement Fund stated it has 36,400 shares. Moreover, Fmr Ltd Liability Com has 0% invested in Chimerix Inc (NASDAQ:CMRX) for 6.94M shares. Panagora Asset Mgmt has 0.01% invested in Chimerix Inc (NASDAQ:CMRX). Sei Investments invested 0% in Chimerix Inc (NASDAQ:CMRX). Millennium Mgmt Ltd Liability Com invested in 620,414 shares. Manufacturers Life Insurance The reported 0% in Chimerix Inc (NASDAQ:CMRX). The North Carolina-based Bank & Trust Of America Corporation De has invested 0% in Chimerix Inc (NASDAQ:CMRX).
Analysts await Chimerix Inc (NASDAQ:CMRX) to report earnings on May, 8. They expect $-0.37 EPS, up 35.09% or $0.20 from last year’s $-0.57 per share. After $-0.32 actual EPS reported by Chimerix Inc for the previous quarter, Wall Street now forecasts 15.63% negative EPS growth.
Among 7 analysts covering Chimerix Inc (NASDAQ:CMRX), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Chimerix Inc has $63 highest and $6 lowest target. $25.78’s average target is 290.02% above currents $6.61 stock price. Chimerix Inc had 16 analyst reports since August 5, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, December 17 by UBS. Barclays Capital downgraded Chimerix Inc (NASDAQ:CMRX) on Tuesday, February 23 to “Equal-Weight” rating. On Tuesday, February 23 the stock rating was maintained by FBR Capital with “Mkt Perform”. FBR Capital downgraded Chimerix Inc (NASDAQ:CMRX) on Monday, December 28 to “Mkt Perform” rating. Barclays Capital maintained it with “Overweight” rating and $12 target in Tuesday, December 29 report. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Monday, October 5. The firm earned “Outperform” rating on Tuesday, August 18 by FBR Capital. The firm earned “Overweight” rating on Monday, December 28 by Piper Jaffray. The stock of Chimerix Inc (NASDAQ:CMRX) earned “Neutral” rating by JP Morgan on Tuesday, December 29. Citigroup initiated Chimerix Inc (NASDAQ:CMRX) on Thursday, September 3 with “Buy” rating.
Chimerix, Inc. is a biopharmaceutical company. The company has market cap of $307.50 million. The Firm is focused on discovering, developing and commercializing oral antivirals. It currently has negative earnings. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.
